Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
M1 Molecule: A Promising Treatment for Optic Nerve Injury
Traumatic injury to the central nervous system (CNS), spinal cord, and optic nerve is the primary cause of disability and the second largest cause of mortality worldwide. CNS injuries frequently result in catastrophic loss of sensory, motor, and visual skills,…
HealthCare Royalty And Clearside Bio to Enter Into Agreement
Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. The money received from the deal will be put to use by Clearside to fund the ongoing clinical testing…
Topcon and OphtAI Collaborate for AI Technology
Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…
Frontera’s Trial for Retinitis Pigmentosa Kicks Off
Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…
FDA Issues Warning Letter to RightEye
The FDA issued a Warning Letter1 on January 31, 2023, to RightEye, LLC, the manufacturer of the RightEye Vision System, for misbranding and adulteration. The RightEye Vision System is a Class II Nystagmograph medical device that has been cleared “recording,…
Regeneron’s EYLEA® Injection Approved for ROP
Regeneron Pharmaceuticals announced that the FDA granted its approval for the use of EYLEA® (aflibercept) Injection as a treatment option for preterm infants suffering from retinopathy of prematurity (ROP). This marks the first time that EYLEA has received approval for…
Endogena Receives FDA Fast Tract Designation for RP
Endogena Therapeutics announced that the US FDA has designated the investigation of its drug EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development program. This process speeds up the availability of new drugs for serious conditions…
Nidek Introduces Cube Alpha Ophthalmic Surgical System
Nidek has introduced the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology for enhanced phacoemulsification. Nidek reports that the Cube α features Gyro torsional technology within its compact design. The torsional ultrasound oscillation enhances the…
Smart Contact Lens That Diagnoses and Treats Glaucoma
A research team at POSTECH has recently developed a wireless theranostic smart contact lens that combines an IOP sensor and a flexible drug delivery system to control IOP measurement and drug administration in glaucoma. Glaucoma is a common eye disease…
FDA Approves Bausch + Lomb’s Photodynamic Laser
Bausch + Lomb and Modulight Corporation, a biomedical laser company, today announced that the FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients…